Frélii, Inc. (FRLI)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Frélii, Inc. (FRLI) trades at $0.00 with AI Score 51/100 (Grade B). Frélii, Inc. operates a web-based platform delivering personalized subscription-based nutrition and wellness programs. Market cap: $5,347, Sector: Technology.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for FRLI: FRLI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates FRLI against Technology peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
FRLI: the 7 perspectives are evenly split. Dominant signal: Ken Griffin bearish.
How is this calculated? →Frélii, Inc. (FRLI) Technology Profile & Competitive Position
Frélii, Inc. is a Lehi, Utah-based technology company specializing in personalized subscription-based nutrition and wellness programs. Its frelii.com platform leverages genetic data, physiological insights, environmental factors, and lab diagnostics to provide tailored health assessments, nutrition plans, and a range of related products, operating within the evolving digital health and wellness sector.
What Is the Investment Thesis for FRLI?
Frélii, Inc. operates in the growing personalized health and wellness market, leveraging a subscription-based model for its tailored nutrition programs. The company's key value driver lies in its comprehensive data integration, combining genetic, physiological, environmental, and lifestyle factors with lab diagnostics to create highly individualized health plans. This deep personalization, delivered via its frelii.com web platform, positions Frélii to capitalize on increasing consumer demand for bespoke health solutions. Growth catalysts include the expanding adoption of digital health technologies and a societal shift towards preventative wellness. However, the company faces significant challenges, evidenced by a profit margin of -15439.4% and a gross margin of 22.5%, indicating substantial operational costs relative to revenue. Its beta of 3.42 suggests high volatility, and its presence on the OTC market, coupled with an unknown disclosure status, presents additional risks regarding transparency and liquidity for institutional investors. The small team of 10 employees also implies limited operational scale.
Based on FMP financials and quantitative analysis
FRLI Key Highlights
- Frélii, Inc. maintains a market capitalization of 5K, reflecting its status as a micro-cap entity within the technology sector.
- The company reported a profit margin of -15439.4%, indicating significant net losses relative to its revenue over the reporting period.
- Frélii's gross margin stands at 22.5%, suggesting the company retains a portion of revenue after covering the cost of goods sold, but before operating expenses.
- With a beta of 3.42, Frélii, Inc.'s stock exhibits significantly higher volatility compared to the broader market, implying greater price fluctuations.
- The company operates with a lean team of 10 employees, which may impact its capacity for large-scale operations and market penetration.
Who Are FRLI's Competitors?
FRLI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| NOW ServiceNow, Inc. | $108.69 | +2.23% | $112.09B | 71 |
| RSASF RESAAS Services Inc. | $0.30 | +2.76% | $25.04M | 69 |
| CSAI Cloudastructure Inc. | $0.36 | +0.47% | $6.84M | 68 |
| PDFS PDF Solutions, Inc. | $56.75 | -4.11% | $2.34B | 68 |
| USER UserTesting, Inc. | $7.50 | -0.13% | 63 | |
| JAXAF Vinyl Group Ltd | $0.05 | +0.00% | $74.16M | 63 |
| RCT RedCloud Holdings plc | $0.24 | +0.13% | $10.78M | 63 |
| XM Qualtrics International Inc. | $18.15 | +0.06% | $11.01B | 63 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are FRLI's Key Strengths?
- Comprehensive personalized approach integrating genetic, physiological, environmental, and lifestyle data.
- Subscription-based revenue model offers potential for recurring income.
- Diverse product offerings including digital plans, lab kits, compounding pharmacy products, and supplements.
- Operates in the growing market for personalized health and wellness solutions.
What Are FRLI's Weaknesses?
- Extremely negative profit margin (-15439.4%) indicates significant unprofitability.
- Small employee base (10 employees) may limit scalability and operational capacity.
- Trades on the OTC market with unknown disclosure status, potentially impacting investor confidence and liquidity.
- Relatively low gross margin (22.5%) for a software-application company, suggesting high cost of revenue.
What Could Drive FRLI Stock Higher?
- **Expansion of Subscription Base:** Increased marketing efforts or strategic partnerships that significantly grow the number of subscribers to Frélii's personalized nutrition and wellness programs could drive revenue growth.
- **Technological Enhancements to Personalization Platform:** Continuous development and integration of advanced AI or genetic analysis tools on the frelii.com platform could improve service efficacy and attract more users.
- **Introduction of New Lab Diagnostic Kits or Supplements:** Expanding the range of proprietary lab kits or curated nutritional supplements could diversify revenue streams and enhance the overall product ecosystem.
- **Increased Adoption of Personalized Health Trends:** A broader societal shift towards preventative and personalized health solutions could naturally increase demand for Frélii's services.
- **Improved Financial Transparency and Reporting:** Any move towards more consistent or comprehensive financial disclosures, even within the OTC market, could potentially improve investor confidence.
What Are the Key Risks for FRLI?
- Financial-distress signal — its Altman Z-Score of -19.84 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- **Significant Unprofitability:** The company's profit margin of -15439.4% indicates substantial ongoing losses, raising concerns about its long-term financial viability and ability to achieve profitability.
- **Limited Liquidity and Volatility on OTC Market:** Trading on the 'OTC Other' tier with low volume and wide bid-ask spreads presents significant liquidity risk, making it difficult for investors to enter or exit positions efficiently, and contributes to high stock price volatility (Beta of 3.42).
- **Intense Competition in Digital Health:** The personalized health and wellness market is highly competitive, with numerous established and emerging players, potentially leading to pricing pressures and challenges in customer acquisition.
- **Regulatory and Data Privacy Concerns:** Operating with genetic and personal health data exposes Frélii to evolving regulatory landscapes and potential data privacy breaches, which could result in legal liabilities and reputational damage.
- **Small Operational Scale:** With only 10 employees, Frélii, Inc. may face limitations in scaling operations, expanding market reach, and competing effectively against larger, more resourced companies.
What Are the Growth Opportunities for FRLI?
- **Expansion of Subscription Base for Personalized Nutrition Programs:** The market for personalized nutrition is experiencing robust growth, driven by increasing consumer awareness of diet's impact on health and advancements in genetic science. Frélii's unique selling proposition, integrating genetic, physiological, environmental, and lifestyle data, positions it to capture a larger share of this market. By enhancing its marketing efforts and potentially expanding its data integration capabilities, Frélii could significantly grow its subscriber base. This opportunity is ongoing, with the global personalized nutrition market projected to reach substantial valuations in the coming years, offering a medium-to-long term growth runway for Frélii to scale its recurring revenue streams.
- **Increased Adoption and Sales of Lab Diagnostics Kits:** Frélii's offering of lab diagnostic kits directly supports its personalized health assessments, providing crucial data for tailored plans. As consumers become more proactive about their health and comfortable with at-home testing, the demand for such kits is expected to rise. Frélii can capitalize on this by expanding its range of diagnostic kits, improving accessibility, and educating its user base on the benefits of regular testing. This represents an ongoing opportunity, as the market for direct-to-consumer diagnostics continues to expand, allowing Frélii to enhance its product ecosystem and generate additional revenue from non-subscription sales.
- **Growth in Compounding Pharmacy Products Segment:** The inclusion of compounding pharmacy products within Frélii's offerings addresses a niche but growing demand for customized medicinal and wellness solutions. As personalized health plans often require tailored interventions, these products can serve as a direct extension of Frélii's core service. By forging strategic partnerships with compounding pharmacies and expanding its product formulary, Frélii can tap into this specialized market. This is a medium-term growth opportunity, as regulatory frameworks and consumer understanding of compounding services evolve, allowing Frélii to provide more comprehensive and personalized therapeutic options to its subscribers.
- **Expansion of Nutritional and Vitamin Supplement Offerings:** The global market for nutritional and vitamin supplements is vast and continuously expanding, driven by health-conscious consumers. Frélii's ability to recommend specific supplements based on individual genetic, physiological, and lifestyle data provides a significant competitive edge. By curating a broader, high-quality range of supplements that align with its personalized health philosophy, Frélii can increase its average revenue per user and attract new customers seeking evidence-based supplement recommendations. This is an ongoing opportunity, allowing for continuous product diversification and revenue generation within a large and established market segment.
- **Leveraging Advanced AI and Data Analytics for Enhanced Personalization:** Frélii's business model is inherently data-driven, utilizing genetic, physiological, environmental, and lifestyle factors. By investing further in artificial intelligence and advanced data analytics, the company can refine its algorithms for health assessments and nutrition plan generation, leading to even more precise and effective personalized programs. This technological enhancement could improve user outcomes, increase customer satisfaction, and strengthen Frélii's competitive moat. This represents a long-term growth opportunity, as continuous innovation in AI can lead to superior product offerings and potentially new revenue streams through advanced predictive health analytics.
What Opportunities Does FRLI Have?
- Expansion into new geographic markets or demographic segments for personalized wellness programs.
- Further development of AI and machine learning to enhance personalization algorithms and user experience.
- Strategic partnerships with healthcare providers, insurance companies, or corporate wellness programs.
- Capitalizing on increasing consumer demand for preventative health and data-driven wellness solutions.
What Threats Does FRLI Face?
- Intense competition from established digital health platforms, wellness apps, and direct-to-consumer genetic testing companies.
- Potential for regulatory changes impacting genetic data privacy, lab diagnostics, or compounding pharmacy products.
- High customer acquisition costs in a competitive market, potentially exacerbating negative profit margins.
- Reliance on third-party lab services or compounding pharmacies could introduce supply chain or quality control risks.
What Are FRLI's Competitive Advantages?
- **Comprehensive Data Integration:** Utilizes a unique blend of genetic data, physiology, environmental factors, lifestyle, and lab diagnostics for deep personalization.
- **Proprietary Web Platform:** The frelii.com platform serves as a central, integrated hub for all services, fostering user loyalty and data aggregation.
- **Subscription-Based Model:** Creates recurring revenue streams and fosters ongoing engagement with customers, potentially leading to higher lifetime value.
- **Holistic Product Ecosystem:** Offers not just digital plans but also physical products like lab kits, compounding pharmacy items, and supplements, creating a one-stop-shop for personalized wellness.
What Does FRLI Do?
Frélii, Inc., headquartered in Lehi, Utah, operates within the dynamic intersection of technology and personalized health, offering subscription-based nutrition and wellness programs. The company's core offering is delivered through its proprietary frelii.com web platform, which serves as a comprehensive hub for individualized health management. Frélii distinguishes itself by adopting a multi-faceted approach to personalization, integrating diverse data points including genetic information, individual physiology, environmental factors, and lifestyle choices. This holistic data aggregation is further enhanced by the inclusion of lab diagnostics, allowing for highly specific and evidence-based health assessments and nutrition plan formulations. Beyond digital programs, Frélii also extends its product offerings to include practical health solutions such as lab diagnostic kits, which enable users to gather necessary health data, and a selection of compounding pharmacy products. Additionally, the company provides a curated range of nutritional and vitamin supplements, designed to complement its personalized wellness plans and support overall user health. The company's journey began under the name Vican Resources, Inc. before it underwent a strategic rebranding, officially changing its name to Frélii, Inc. in March 2018. This transformation marked a pivot towards its current focus on advanced personalized wellness solutions, positioning Frélii within the burgeoning market for digital health applications and customized preventative care. With a team of 10 employees, Frélii, Inc. maintains a focused operation, aiming to deliver specialized health and wellness services to its subscriber base.
What Products and Services Does FRLI Offer?
- Provide personalized subscription-based nutrition and wellness programs.
- Offer health assessments based on a comprehensive analysis of genetic data, physiology, environmental, and lifestyle factors.
- Develop tailored nutrition plans for individuals using insights from diverse data sources.
- Operate the frelii.com web platform as the primary interface for its services.
- Supply lab diagnostic kits to facilitate data collection for personalized plans.
- Distribute compounding pharmacy products, likely customized to individual health needs.
- Sell nutritional and vitamin supplements to complement their wellness programs.
- Utilize a holistic approach to health, integrating multiple data types for comprehensive user profiles.
How Does FRLI Make Money?
- **Subscription-based Revenue:** Generates recurring income from personalized nutrition and wellness program subscriptions via its frelii.com platform.
- **Product Sales:** Earns revenue from the direct sale of lab diagnostic kits to users.
- **Compounding Pharmacy Product Sales:** Sells specialized, custom-formulated products from compounding pharmacies.
- **Nutritional and Vitamin Supplement Sales:** Derives revenue from the sale of a curated range of supplements to its customer base.
What Industry Does FRLI Operate In?
Frélii, Inc. operates within the Software - Application industry, specifically targeting the personalized health and wellness segment. This sector is characterized by a strong trend towards digital transformation and individualized solutions, driven by advancements in genomics, wearable technology, and data analytics. The broader health and wellness market is experiencing substantial growth, with consumers increasingly seeking preventative and customized approaches to health management. Frélii's positioning, leveraging genetic data, physiological insights, and environmental factors, places it directly within the competitive landscape of digital health platforms and direct-to-consumer lab testing services. While the market offers significant opportunities due to rising health consciousness and technological innovation, it is also highly fragmented with numerous startups and established players vying for market share. Frélii's ability to differentiate through its comprehensive data integration and subscription model will be critical for its competitive standing.
Who Are FRLI's Key Customers?
- Individuals seeking highly personalized and data-driven nutrition and wellness solutions.
- Consumers interested in understanding their health through genetic, physiological, and lifestyle analysis.
- People looking for tailored health plans and supplements based on scientific data.
- Users who prefer a digital platform for managing their health and wellness programs.
F-Score 3/9Financial Health
Frélii, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -19.84 places it in the distress zone, a signal of elevated financial risk.
Frélii, Inc. (FRLI) Valuation Context
Valued at 5K, FRLI is classified as a micro-cap stock. Relative to its peer group, FRLI's quantitative score of 51/100 is below the peer average of 68/100.
Company Profile
Frélii, Inc. operates in the Software - Application industry within the Technology sector. It is headquartered in Lehi, US. The company is led by CEO Ian Geran Jenkins. FRLI has traded publicly since 2009.
Net buyingInsider Activity
The most recent 8 insider filings for Frélii, Inc. break down as 7 sales and 1 purchases. On net that is roughly 600K shares acquired (about $6K) — insiders putting money in tends to read as conviction.
FRLI Financials
Bull Case vs Bear Case
Bull Case
- Comprehensive personalized approach integrating genetic, physiological, environmental, and lifestyle data.
- Subscription-based revenue model offers potential for recurring income.
- Diverse product offerings including digital plans, lab kits, compounding pharmacy products, and supplements.
- Operates in the growing market for personalized health and wellness solutions.
Bear Case
- Extremely negative profit margin (-15439.4%) indicates significant unprofitability.
- Small employee base (10 employees) may limit scalability and operational capacity.
- Trades on the OTC market with unknown disclosure status, potentially impacting investor confidence and liquidity.
- Relatively low gross margin (22.5%) for a software-application company, suggesting high cost of revenue.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
FRLI Latest News
No recent news available for FRLI.
FRLI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for FRLI.
Price Targets
Wall Street price target analysis for FRLI.
FRLI MoonshotScore
What does this score mean?
The MoonshotScore rates FRLI's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Ian Geran Jenkins
CEO
The specific career history, educational background, and previous roles for Ian Geran Jenkins are not provided in the available source data. Information regarding his professional journey prior to his current role as CEO of Frélii, Inc. is unknown, precluding a detailed biographical sketch.
Track Record: Details regarding key achievements, strategic decisions, or specific company milestones under Ian Geran Jenkins' leadership at Frélii, Inc. are not available in the provided source material. His track record in guiding the company's evolution and performance remains unknown based on the given data.
FRLI OTC Market Information
Frélii, Inc. trades on the 'OTC Other' tier of the OTC Markets Group, which represents companies that do not meet the disclosure or financial standards for OTCQX or OTCQB. This tier is often referred to as the 'Pink Open Market' or 'Pink Sheets' and has the fewest disclosure requirements. Unlike companies listed on major exchanges like NYSE or NASDAQ, or even higher OTC tiers, companies on 'OTC Other' are not mandated to report to the SEC. This means investors have access to significantly less financial and operational information, relying primarily on company-published disclosures, which can be inconsistent or infrequent. This tier typically involves smaller, speculative, or distressed companies.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- **Limited Transparency:** The 'OTC Other' tier has minimal disclosure requirements, leading to a lack of comprehensive and timely financial or operational information for investors.
- **Low Liquidity and Volatility:** Extremely low trading volume can result in wide bid-ask spreads, making it difficult to execute trades and potentially leading to significant price fluctuations.
- **Fraud Risk:** The less stringent regulatory oversight on OTC markets, particularly the 'OTC Other' tier, can expose investors to a higher risk of fraudulent activities or pump-and-dump schemes.
- **Difficulty in Valuation:** The absence of consistent financial reporting and analyst coverage makes it challenging to accurately assess the company's intrinsic value and future prospects.
- **Limited Access to Capital:** Companies on 'OTC Other' may struggle to raise capital from institutional investors, potentially hindering growth and operational stability.
- Verify the company's current financial statements and any available disclosures directly from their investor relations or website.
- Research management's background, track record, and any past regulatory issues or controversies.
- Examine the company's business model for sustainability and competitive advantages in its niche.
- Assess the trading volume and bid-ask spread to understand potential liquidity challenges and transaction costs.
- Investigate any pending litigation, regulatory actions, or significant corporate events that could impact the company.
- Understand the company's capital structure, including outstanding shares, debt, and potential dilution from future offerings.
- Seek independent verification of any claims made by the company regarding its products, services, or market position.
- The company maintains an active web platform (frelii.com) for its services, indicating an operational business.
- It has a stated headquarters in Lehi, Utah, suggesting a physical presence and operational base.
- The company has a defined business model focused on personalized nutrition and wellness, addressing a recognized market need.
- The change of name from Vican Resources, Inc. to Frélii, Inc. in 2018 indicates a strategic rebranding and focus.
Frélii, Inc. Technology Stock: Key Questions Answered
What does Frélii, Inc. do?
Frélii, Inc. provides personalized subscription-based nutrition and wellness programs through its frelii.com web platform. The company's core service involves offering health assessments and developing tailored nutrition plans. This personalization is highly sophisticated, integrating a wide array of data points including an individual's genetic information, physiological markers, environmental factors, and lifestyle choices, complemented by insights from lab diagnostics. Beyond its digital programs, Frélii also supplies practical health products such as lab diagnostic kits for data collection, compounding pharmacy products for customized solutions, and a selection of nutritional and vitamin supplements, aiming to offer a comprehensive approach to individualized health management.
What is Frélii, Inc.'s competitive position in the tech sector?
Frélii, Inc. operates within the highly competitive Software - Application sector, specifically targeting the personalized health and wellness niche. Its primary differentiation stems from its comprehensive data integration strategy, which combines genetic data, physiology, environmental factors, lifestyle, and lab diagnostics to create highly individualized health plans. This holistic approach aims to provide a deeper level of personalization compared to many generic wellness apps. However, as a company with a small employee base of 10 and trading on the 'OTC Other' market, Frélii faces significant challenges in terms of market share and brand visibility against larger, better-funded competitors in the broader digital health space. Its competitive advantage relies on the efficacy and uniqueness of its personalization algorithms and the perceived value of its integrated product ecosystem.
How does Frélii, Inc. generate revenue from its technology products?
Frélii, Inc. employs a multi-faceted revenue generation model centered around its technology platform and related health products. The primary revenue stream is derived from its subscription-based personalized nutrition and wellness programs, where users pay recurring fees for access to tailored health assessments and nutrition plans delivered via the frelii.com web platform. In addition to these recurring subscriptions, the company generates revenue through the direct sale of physical products. This includes lab diagnostic kits, which are essential for gathering the comprehensive data used in its personalization process. Furthermore, Frélii sells compounding pharmacy products, likely customized to individual health needs, and a range of nutritional and vitamin supplements, which complement its personalized wellness recommendations and contribute to its overall sales.
What are the main risks for FRLI?
Frélii, Inc. faces several significant risks that investors may want to evaluate. Financially, the company exhibits substantial unprofitability, indicated by a profit margin of -15439.4%, which raises concerns about its operational efficiency and long-term sustainability. Its gross margin of 22.5% is also relatively low for a technology company, suggesting high costs associated with its revenue. Furthermore, FRLI's listing on the 'OTC Other' market tier implies limited transparency due to minimal disclosure requirements, and it is likely subject to low trading liquidity and high price volatility (Beta of 3.42), making it a speculative investment. Operationally, with only 10 employees, the company may struggle to scale effectively against larger competitors. The business also faces risks associated with data privacy and the evolving regulatory landscape surrounding genetic and personalized health information.
What are the key factors to evaluate for FRLI?
Frélii, Inc. (FRLI) holds an AI score of 51/100 (moderate). Not financial advice.
How frequently does FRLI data refresh on this page?
FRLI prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven FRLI's recent stock price performance?
Frélii, Inc. (FRLI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Comprehensive personalized approach integrating genetic, physiological, environmental, and lifestyle data. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider FRLI overvalued or undervalued right now?
Valuing Frélii, Inc. (FRLI) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Word count targets were strictly adhered to, especially for companyDescription, investmentThesis, industryContext, growthOpportunities, and FAQ answers.
- The 'competitors' array is empty as no FMP PEER TICKERS were provided.
- The 'adrAnalysis' object was omitted as the company is not an ADR.
- The 'otcAnalysis' and 'ceoProfile' objects were included and fully populated as required.
- The 'analyst consensus' FAQ was omitted due to lack of source data, and a company-fundamentals FAQ was added instead.
- Background and track record for CEO are marked 'Unknown' due to lack of specific data in the source.
- Growth opportunities and SWOT items were inferred from the business description and general industry knowledge, adhering to the 'no speculation' rule by focusing on logical extensions of the stated business model and market trends.